Pediatric Blood Pressure: AAP 2017 Guidelines, Percentiles, and Hypertension Staging

Pediatric hypertension is an underrecognized condition with significant implications for lifelong cardiovascular health. The overall prevalence of hypertension in childhood is 2% to 5%, with approximately 13% to 18% prevalence of elevated blood pressure in the general pediatric population. A 2025 systematic review and meta-analysis of 271 studies involving over 3.6 million children confirmed a global prevalence of 3.89% for sustained hypertension (confirmed on ≥3 occasions) and 11.85% for occasional hypertension (single-visit diagnosis), highlighting the importance of confirmatory measurements.

The American Academy of Pediatrics (AAP) 2017 Clinical Practice Guideline provides comprehensive recommendations for screening and management of high blood pressure in children and adolescents. Key changes from the 2004 Fourth Report include:

• Replacement of "prehypertension" with "elevated blood pressure"
• New normative BP tables based on normal-weight children (excluding overweight/obese children from reference data)
• Simplified screening table for identifying BPs needing further evaluation
• Simplified BP classification in adolescents ≥13 years that aligns with adult guidelines
• More limited recommendation to perform screening BP measurements only at preventive care visits
• Expanded role for ambulatory blood pressure monitoring (ABPM) in diagnosis and management
• Revised recommendations on echocardiography (generally only before medication initiation)

Blood Pressure Categories and Staging

For children aged 1 to <13 years:

• Normal BP: <90th percentile for age, sex, and height
• Elevated BP: ≥90th percentile to <95th percentile, or 120/80 mm Hg to <95th percentile (whichever is lower)
• Stage 1 HTN: ≥95th percentile to <95th percentile + 12 mm Hg, or 130/80 to 139/89 mm Hg (whichever is lower)
• Stage 2 HTN: ≥95th percentile + 12 mm Hg, or ≥140/90 mm Hg (whichever is lower)

For children aged ≥13 years:

• Normal BP: <120/<80 mm Hg
• Elevated BP: 120/<80 to 129/<80 mm Hg
• Stage 1 HTN: 130/80 to 139/89 mm Hg
• Stage 2 HTN: ≥140/90 mm Hg

Use the AAP BP 2017 calculator to classify blood pressure using age, sex, and height percentiles.

Screening Recommendations

Children should have BP measured annually beginning at age 3 years during well-child visits. Children younger than 3 years should have BP measured only if they have risk factors: history of prematurity, very low birth weight, congenital heart disease, recurrent urinary tract infections, renal disease, solid organ transplant, malignancy, or medications known to raise BP.

Measurement Technique

BP should be measured with an appropriately sized cuff (bladder length 80–100% of arm circumference, width at least 40% of arm circumference). When the initial BP measurement is abnormal, repeat measurement by auscultation is recommended within the same visit if possible. Best practice is to obtain up to 3 BP measurements and record the average of the latter 2 measurements unless the first measurement is normal.

Diagnosis Confirmation

Hypertension is defined as average clinic-measured SBP and/or DBP ≥95th percentile on 3 separate visits. For stage 1 HTN, if BP remains elevated after 3 visits, ABPM should be ordered (if available), diagnostic evaluation conducted, and treatment initiated.

Ambulatory Blood Pressure Monitoring

ABPM is recommended to confirm the diagnosis of hypertension before starting antihypertensive medication. ABPM is more accurate for diagnosis than clinic-measured BP, more predictive of future BP, and can assist in detection of secondary hypertension. Increased left ventricular mass index and left ventricular hypertrophy correlate more strongly with ABPM parameters than casual BP.

Height Adjustment: Why It Matters

BP levels should be interpreted on the basis of sex, age, and height to avoid misclassification of children who are either extremely tall or extremely short. Two children of the same age with identical BP readings can be in different categories based on height percentile. The normative data were collected using an auscultatory technique, which may provide different values than oscillometric devices or ABPM.

The AAP BP Full calculator provides height-adjusted percentiles with complete normative data.

White Coat Hypertension

White coat hypertension (WCH) is defined as BP ≥95th percentile in the office but <95th percentile outside the clinical setting. It is estimated that up to half of children evaluated for elevated office BP have WCH. A 2026 meta-analysis found the pooled prevalence of white coat hypertension was 5.17% (95% CI 3.23–7.52), with higher prevalence in low- and middle-income countries (8.13%) than high-income countries (3.70%).

WCH is diagnosed by ABPM when mean SBP and DBP are <95th percentile and BP load is <25%. While WCH is associated with only slightly increased risk of adverse outcomes compared with normotension, abnormal BP response to exercise and increased left ventricular mass have been found in children with WCH. Children with WCH should have screening BP measured at regular well-child visits with consideration of repeat ABPM in 1–2 years.

Masked Hypertension

Masked hypertension — normal office BP but elevated ambulatory BP — was present in 9.22% (95% CI 6.90–11.83) of children and adolescents in a 2026 meta-analysis. This condition is of particular concern and requires additional monitoring, especially if other risk factors are present.

Secondary Hypertension: When to Evaluate

Secondary hypertension should be considered in:

• Younger children (particularly <6 years)
• Stage 2 or resistant hypertension
• Symptomatic hypertension
• Evidence of acute, severe, or malignant hypertension with target organ injury

A 2023 JAMA systematic review found that in primary care settings, the prevalence of secondary hypertension was 9.0% (95% CI 4.5–15.0%), while in subspecialty clinics it was 44% (95% CI 36–53%).

Clinical Findings Associated with Secondary Hypertension

• Family history of secondary hypertension (LR 4.7)
• Weight ≤10th percentile for age and sex (LR 4.5)
• History of prematurity (LR 2.3–2.8)
• Age ≤6 years (LR 2.2–2.6)
• Microalbuminuria (LR 13)
• Serum uric acid ≤5.5 mg/dL (LR 2.1–6.3)

Findings Associated with Decreased Likelihood of Secondary Hypertension

• Asymptomatic presentation (LR 0.19–0.36)
• Obesity (LR 0.34)
• Family history of any hypertension (LR 0.42)

Initial Evaluation

The AAP recommends the following initial workup for confirmed hypertension:

• Urinalysis, serum electrolytes, BUN, serum creatinine, lipid panel
• Renal ultrasound
• Hemoglobin A1c, liver enzymes, fasting lipid panel

Additional testing (fasting glucose, TSH, drug screening, sleep study, plasma renin/aldosterone, catecholamines, renovascular imaging) should be considered based on clinical suspicion.

Treatment Approach

Lifestyle Modifications

Lifestyle changes are indicated for all youth with high BP regardless of underlying diagnosis, including:

• Dietary modification (DASH-style diet, sodium restriction)
• Increased physical activity
• Weight management if overweight or obese

A 6-month trial of non-pharmacological management is typically recommended before starting antihypertensive medications in most cases.

Indications for Pharmacologic Treatment

Antihypertensive medications should be initiated in children who:

• Remain hypertensive despite a trial of lifestyle modifications
• Have symptomatic hypertension (headaches, cognitive changes)
• Have stage 2 hypertension without a clearly modifiable factor (e.g., obesity)
• Have any stage of hypertension associated with CKD or diabetes mellitus
• Have evidence of left ventricular hypertrophy on echocardiography

An echocardiogram should be obtained to assess cardiac mass before antihypertensive medications are started.

Choice of Antihypertensive Agent

Pharmacologic treatment should be initiated with:

• ACE inhibitor (e.g., lisinopril, enalapril)
• ARB (e.g., losartan)
• Long-acting calcium channel blocker
• Thiazide diuretic

A network meta-analysis showed that ACE inhibitors and ARBs are superior to placebo for BP reduction in children, with lisinopril and enalapril demonstrating the strongest evidence. Beta-blockers are not recommended as initial treatment due to expanded adverse effect profile and lack of association with improved outcomes compared with other agents.

Important Considerations

• African American children may not have as robust a response to ACE inhibitors; consider higher initial dose or alternative agent
• ACE inhibitors and ARBs are contraindicated in pregnancy; adolescents of childbearing potential should be counseled
• For children with CKD, proteinuria, or diabetes, an ACE inhibitor or ARB is recommended as initial therapy

Treatment Targets

The primary aim is to reach and maintain BP:

• <90th percentile for age, sex, and height in children <13 years
• <130/80 mm Hg in children ≥13 years
• More stringent targets for children with secondary hypertension or high-risk conditions (e.g., CKD)

Long-Term Implications

Hypertensive children are highly likely to become hypertensive adults and to have measurable target organ injury, particularly left ventricular hypertrophy and vascular stiffening. Data on BP tracking from childhood to adulthood demonstrate that higher BP in childhood correlates with higher BP in adulthood and the onset of hypertension in young adulthood.

Key Clinical Priorities

1. Screen annually starting at age 3 during well-child visits; earlier if risk factors present.
2. Use height-adjusted percentiles for children <13 years — the same BP can be normal in a tall child and hypertensive in a short child.
3. Confirm diagnosis on 3 separate visits before labeling a child as hypertensive; single-visit diagnosis overestimates prevalence by 3-fold.
4. Use ABPM to confirm hypertension before starting medications — up to 50% of children with elevated office BP have white coat hypertension.
5. Proper measurement technique is essential: appropriately sized cuff, 5-minute rest, auscultatory confirmation of abnormal readings.
6. Evaluate for secondary causes in children <6 years, those with stage 2 hypertension, or those with symptoms.
7. Lifestyle modifications first for 6 months unless symptomatic, stage 2, or comorbid CKD/diabetes.
8. ACE inhibitors or ARBs are preferred first-line agents based on network meta-analysis evidence.
9. Obtain echocardiogram before starting antihypertensive medications to assess for LVH.
10. Target BP <90th percentile (or <130/80 in adolescents ≥13 years) with more stringent goals for high-risk patients.

Accurate diagnosis and appropriate management of pediatric hypertension requires methodological rigor in BP measurement, confirmation across multiple visits, and recognition that primary hypertension is now the most common cause in children and adolescents, particularly those with obesity.

References

1. Falkner B, Gidding SS, Baker-Smith CM, et al. Pediatric Primary Hypertension: An Underrecognized Condition: A Scientific Statement From the American Heart Association. Hypertension. 2023;80(6):e101-e111.
2. Ruan X, Zhu A, Wang T, et al. Global Prevalence of Hypertension in Children and Adolescents Younger Than 19 Years. JAMA Pediatr. 2025;179(9):987-999.
3. Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics. 2017;140(3):e20171904.
4. Hampl SE, Hassink SG, Skinner AC, et al. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity. Pediatrics. 2023;151(2):e2022060640.
5. US Preventive Services Task Force, Krist AH, Davidson KW, et al. Screening for High Blood Pressure in Children and Adolescents: US Preventive Services Task Force Recommendation Statement. JAMA. 2020;324(18):1878-1883.
6. Zhou J, Shan S, Wu J, et al. Global Prevalence of Hypertension Among Children and Adolescents Aged 19 Years or Younger: An Updated Systematic Review and Meta-Analysis. Lancet Child Adolesc Health. 2026;10(1):11-21.
7. Chanchlani R, Brady T, Kruger R, Sinha MD. Under Pressure: The Lifelong Cardiovascular Health of Children and Youth With Primary Hypertension. Lancet Child Adolesc Health. 2025;S2352-4642(25)00302-5.
8. Nugent JT, Jiang K, Funaro MC, et al. Does This Child With High Blood Pressure Have Secondary Hypertension? The Rational Clinical Examination Systematic Review. JAMA. 2023;329(12):1012-1021.
9. Riley M, Hernandez AK, Kuznia AL. High Blood Pressure in Children and Adolescents. Am Fam Physician. 2018;98(8):486-494.
10. Burrello J, Erhardt EM, Saint-Hilary G, et al. Pharmacological Treatment of Arterial Hypertension in Children and Adolescents: A Network Meta-Analysis. Hypertension. 2018;72(2):306-313.